Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CI-1040

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

MEK inhibitor

Related drugs:

KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
NF1 deletion	Acute Myelogenous Leukemia	NF1 deletion	Acute Myelogenous Leukemia	CI-1040 Resistant: D – Preclinical CI-1040 Resistant : D	CI-1040 Resistant: D – Preclinical CI-1040 Resistant : D
EGFR exon 19 deletion + NRAS Q61K	Lung Adenocarcinoma	EGFR exon 19 deletion + NRAS Q61K	Lung Adenocarcinoma	gefitinib + CI-1040 Sensitive: D – Preclinical gefitinib + CI-1040 Sensitive : D	gefitinib + CI-1040 Sensitive: D – Preclinical gefitinib + CI-1040 Sensitive : D
KRAS mutation	Multiple Myeloma	KRAS mutation	Multiple Myeloma	CI-1040 + PI-103 Sensitive: D – Preclinical CI-1040 + PI-103 Sensitive : D	CI-1040 + PI-103 Sensitive: D – Preclinical CI-1040 + PI-103 Sensitive : D
BRAF mutation	Ovarian Cancer	BRAF mutation	Ovarian Cancer	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
GNAQ Q209P	Melanoma	GNAQ Q209P	Melanoma	CI-1040 Resistant: D – Preclinical CI-1040 Resistant : D	CI-1040 Resistant: D – Preclinical CI-1040 Resistant : D
PTEN deletion	Melanoma	PTEN deletion	Melanoma	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	dasatinib + CI-1040 Sensitive: D – Preclinical dasatinib + CI-1040 Sensitive : D	dasatinib + CI-1040 Sensitive: D – Preclinical dasatinib + CI-1040 Sensitive : D
RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	CI-1040 + SU6656 Sensitive: D – Preclinical CI-1040 + SU6656 Sensitive : D	CI-1040 + SU6656 Sensitive: D – Preclinical CI-1040 + SU6656 Sensitive : D
RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	CI-1040 + PP2 Sensitive: D – Preclinical CI-1040 + PP2 Sensitive : D	CI-1040 + PP2 Sensitive: D – Preclinical CI-1040 + PP2 Sensitive : D
HRAS G13R	Thyroid Gland Anaplastic Carcinoma	HRAS G13R	Thyroid Gland Anaplastic Carcinoma	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
BRAF V600E	Thyroid Gland Medullary Carcinoma	BRAF V600E	Thyroid Gland Medullary Carcinoma	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D
RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D	CI-1040 Sensitive: D – Preclinical CI-1040 Sensitive : D